Skip to Content
Home > About Us > Research and Grants Administration > Detail
<< Back to Results
This research is being done because even with the most aggressive after surgery treatment with chemotherapy, many people still have the lung cancer recur (come back).
The purpose of this study is to determine if adding the new drug bevacizumab to chemotherapy improves the chance for cure for patients who have had surgery for the removal of the lung cancer. The study will compare the effects (good and bad) of adding bevacizumab to chemotherapy with standard chemotherapy alone on patients with lung cancer to see which is better at preventing the cancer from coming back. The drug bevacizumab has not yet been Food and Drug Administration (FDA) approved for treatment of lung cancer that has been removed. It has been FDA approved for lung cancer that has come back or spread beyond the lung.
View Additional Section Content
For more information about our research program and IRB, please contact: